3.77
-0.0136(-0.36%)
Currency In USD
| Previous Close | 3.79 |
| Open | 3.72 |
| Day High | 3.99 |
| Day Low | 3.72 |
| 52-Week High | 29.45 |
| 52-Week Low | 2.85 |
| Volume | 5,855 |
| Average Volume | 58,049 |
| Market Cap | 2.78M |
| PE | 0 |
| EPS | 3,635 |
| Moving Average 50 Days | 3.45 |
| Moving Average 200 Days | 5.27 |
| Change | -0.01 |
If you invested $1000 in Qualigen Therapeutics, Inc. (QLGN) since IPO date, it would be worth $0.01 as of May 24, 2025 at a share price of $3.773. Whereas If you bought $1000 worth of Qualigen Therapeutics, Inc. (QLGN) shares 5 years ago, it would be worth $0.97 as of May 24, 2025 at a share price of $3.773.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
GlobeNewswire Inc.
May 19, 2025 9:25 PM GMT
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Mark
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
GlobeNewswire Inc.
May 01, 2025 8:20 PM GMT
CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Mark
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
GlobeNewswire Inc.
Apr 01, 2025 12:00 PM GMT
CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM). Qualigen and Marizyme